Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces the dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron^® Treatment of Chemotherapy-Induced Neuropathic Pain), evaluating Halneuron^® for the treatment of neuropathic pain associated with prior chemotherapy treatment (“CINP”).

Read more at globenewswire.com